Guggenheim lowered the firm’s price target on Valneva (VALN) to $11 from $13 and keeps a Buy rating on the shares. The firm adjusted estimates as part of a Q1 earnings preview for commercial-stage companies in its biotechnology coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
- Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate
- Jefferies says Valneva stock weakness presents buying opportunity
- Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
- Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial